Biodesix Inc. (BDSX): Price and Financial Metrics
BDSX Price/Volume Stats
| Current price | $1.53 | 52-week high | $3.00 |
| Prev. close | $1.41 | 52-week low | $0.96 |
| Day low | $1.37 | Volume | 62,100 |
| Day high | $1.54 | Avg. volume | 92,585 |
| 50-day MA | $1.59 | Dividend yield | N/A |
| 200-day MA | $1.67 | Market Cap | 120.04M |
BDSX Stock Price Chart Interactive Chart >
BDSX POWR Grades
- Growth is the dimension where BDSX ranks best; there it ranks ahead of 82.6% of US stocks.
- BDSX's strongest trending metric is Stability; it's been moving up over the last 179 days.
- BDSX ranks lowest in Momentum; there it ranks in the 4th percentile.
BDSX Stock Summary
- BIODESIX INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 95.69% of US listed stocks.
- With a year-over-year growth in debt of 214.17%, BIODESIX INC's debt growth rate surpasses 93.44% of about US stocks.
- BIODESIX INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -68.15%, greater than the shareholder yield of only 8.06% of stocks in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to BIODESIX INC are DERM, BIOL, SKYT, NCR, and PRCH.
- BDSX's SEC filings can be seen here. And to visit BIODESIX INC's official web site, go to www.biodesix.com.
BDSX Valuation Summary
- In comparison to the median Healthcare stock, BDSX's price/sales ratio is 4.55% higher, now standing at 2.3.
- Over the past 31 months, BDSX's EV/EBIT ratio has gone up 11.9.
Below are key valuation metrics over time for BDSX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BDSX | 2023-05-23 | 2.3 | 20.2 | -1.3 | -1.8 |
| BDSX | 2023-05-22 | 2.2 | 19.3 | -1.3 | -1.7 |
| BDSX | 2023-05-19 | 2.2 | 19.8 | -1.3 | -1.8 |
| BDSX | 2023-05-18 | 2.2 | 19.6 | -1.3 | -1.7 |
| BDSX | 2023-05-17 | 2.3 | 20.9 | -1.4 | -1.8 |
| BDSX | 2023-05-16 | 2.4 | 21.6 | -1.4 | -1.9 |
BDSX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- BDSX has a Quality Grade of C, ranking ahead of 33.79% of graded US stocks.
- BDSX's asset turnover comes in at 0.8 -- ranking 34th of 81 Healthcare stocks.
- 500 - Internal server error
The table below shows BDSX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.80 | 0.430 | -0.914 |
| 2020-12-31 | 0.56 | 0.517 | -0.964 |
BDSX Price Target
For more insight on analysts targets of BDSX, see our BDSX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $25.33 | Average Broker Recommendation | 1.12 (Strong Buy) |
Biodesix Inc. (BDSX) Company Bio
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. It offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer; and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It is a data-driven diagnostic solutions company with proprietary AI platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. The firm offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. . The company was founded in 2005 and is headquartered in Boulder, CO.
Latest BDSX News From Around the Web
Below are the latest news stories about BIODESIX INC that investors may wish to consider to help them evaluate BDSX as an investment opportunity.
Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual MeetingBOULDER, Colo., June 01, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR) featuring genomic data contributed by Biodesix and other organizations. |
Biodesix to Participate in William Blair’s 43rd Annual Growth Stock ConferenceBOULDER, Colo., May 31, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at William Blair’s 43rd Annual Growth Stock Conference, which will be held from June 6-8, 2023. |
Jack Schuler Spends US$65k On Biodesix Stock \Whilst it may not be a huge deal, we thought it was good to see that the Biodesix, Inc. ( NASDAQ:BDSX ) Independent... |
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® TestingBOULDER, Colo., May 25, 2023--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health economic benefits of the Nodify CDT® and Nodify XL2® tests in the management of pulmonary nodules. The posters, presented May 8-9, 2023, highlighted potential cost savings i |
Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of DirectorsBOULDER, Colo., May 24, 2023--Biodesix, Inc. a leading diagnostics company, is proud to announce that its Chief Financial Officer, Robin Harper Cowie, has been appointed to the Colorado BioScience Association (CBSA) board of directors. As a seasoned executive with extensive experience in the life sciences sector, Ms. Harper Cowie's expertise will play a crucial role in driving the growth and development of Colorado's thriving life sciences community. In joining the CBSA board, Ms. Harper Cowie w |
BDSX Price Returns
| 1-mo | -5.56% |
| 3-mo | 0.66% |
| 6-mo | 9.29% |
| 1-year | -14.53% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -33.48% |
| 2022 | -56.52% |
| 2021 | -73.76% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...